Published on British Columbia Drug and Poison Information Centre (BC DPIC) ( http://www.dpic.org)

Home > Drug Product Listings > Doxepin > Printer-friendly PDF

Doxepin

Trade Name: Silenor Manufacturer/Distributor: Paladin Labs www.paladin-labs.com 1-888-376-7830 Classification: Hypnotic ATC Class: N06AA - doxepin Status: active Notice of Compliance (yyyy/mm/dd): 2012/21/13 Date Marketed in Canada (yyyy/mm/dd): 2012/01/08 Presentation: Tablet: 3 mg. DIN: 02398257 Tablet: 6 mg. DIN: 02398265 Comments: Silenor is indicated for the treatment and symptomatic relief of insomnia characterized by frequent nocturnal awakening, and/or early morning awakenings. Keywords: doxepin sleep disorders hypnotics & sedatives Access: public Back to: Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database Status: ?

Search Terms: Apply A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4) Date Marketed in Common Generic Name Classification Canada Trade Name(s) (yyyy/mm/dd) Alpha adrenergic Guanfacine HCl Intuniv XR receptor agonist for 2013/08/06 ADHD Heparin Sodium Hepalean Heparin anticoagulant Isopto Homatropine Mydriatic agent Homatropine Human Papillomavirus Cervarix Vaccine 2010/02/05 Vaccine Hydrocodone + phenylephrine + Hycomine Syrup Narcotic 2011/05/11 pyrilamine + ammonium chloride Hydrocodone resin with Tussionex Narcotic phenyltoloxamine tablets Dilaudid injection; Hydromorphone Narcotic Dilaudid HP injection Hydromorphone Jurnista opioid anaglesic 2010/04/13 hydrochloride Hydromorphone Hydromorph Opioid analgesic 2011/04/01 hydrochloride Contin Hydroxocobalamin Cyanokit Antidote 2011/05/24 Ibuprofen Caldolor NSAID 2012/05 Ibuprofen & Muscle Summit Ultra 2012/03/14 Methocarbamol relaxant/analgesic Immune response Imiquimod Vyloma 2011/05/04 modifier Indacaterol + Enerzair glycopyrronium bromide Asthma medication 2020/11/05 Breezhaler + mometasone Onbrez Long-acting beta 2 Indacaterol maleate 2012/03 Breezhaler agonist Date Marketed in Common Generic Name Classification Canada Trade Name(s) (yyyy/mm/dd) Indomethacin Indomethacin NSAID 2011/11/15 P.D.A. Biological response Infliximab Avsola 2020/06/01 modifier Influenza Vaccine Intanza Vaccine 2010/08/01 Influenza Vaccine Flumist Vaccine 2010/08/13 Influenza Vaccine Agriflu Vaccine 2010/09/01 Influenza vaccine Fluad Influenza vaccine 2011/08/25 Insulin aspart + Fiasp Insulin analogue 2017/04/06 niacinamide Biologic response Interferon beta-1b Extavia 2010/05/17 modifier Ipilimumab Yervoy Antineoplastic agent 2012/03 Iron isomaltoside Monoferric Iron preparation 2018/06/22 Antineoplastic agent, Isatuximab Sarclisa 2020/07/03 monoclonal antibody Isotretinoin Epuris Acne therapy 2013-03-14 Ivabradine Lancora Cardiac medication 2017/04 Cystic fibrosis transmembrane Ivacaftor Kalydeco 2012/12/01 conductance regulator potentiator Cystic Fibrosis Transmembrane Ivacaftor + tezacaftor Symdeko Conductance Regulator 2018/06/27 Correctors and Potentiators Ivermectin Rosiver Topical rosacea therapy 2015/05/25 Ivermectin Stromectol Anthelmintic 2018/11/07 Ixazomib Ninlaro Antineoplastic agent 2016/09/21 Ixekizumab Taltz Immunomodulator 2018/03/29 Ketorolac tromethamine Acuvail Topical NSAID 2011/10/01 Lacosamide Vimpat Anticonvulsant 2010/10/21 « first? previous ? 2 3 4 5 6 7 8 9 10 ? next ? last » © 2017 BC Drug and Poison Information Centre

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is not meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the full terms and conditions below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases. Terms and Conditions

Source URL (retrieved on 2021-09-29 18:02): http://www.dpic.org/druglisting/doxepin